Secreted factors of Aspergillus fumigatus cause lung epithelial barrier disruption: A study using an air-liquid interface cell culture model.

IF 2.7 3区医学 Q3 INFECTIOUS DISEASES

Medical mycology Pub Date : 2025-02-28 DOI:10.1093/mmy/myaf018

Bianca Carla Silva Campitelli Barros, Debora Tereza Lucas Barros, Matthias Brock, Marcos Sergio Toledo, Solange Maria Toledo Serrano, Erika Suzuki, Amir M Ghaemmaghami

引用次数: 0

Abstract

The effects of Aspergillus fumigatus-conditioned medium (AFCM) on the integrity of the Calu-3 cell lung epithelial barrier were investigated. AFCM led to a decrease in transepithelial electrical resistance and the disruption of the occludin network in the epithelial barrier. Preincubation with protease inhibitors reduced the effect of AFCM by ~ 90%, demonstrating the role of fungal proteases in epithelial barrier disruption. By mass spectrometry, we identified 494 unique proteins in AFCM, including 14 peptidases of different families. Together, these findings suggest that proteases secreted by A. fumigatus were able to modulate host epithelial barrier disruption in this fungal infection process.

查看原文本刊更多论文

曲霉菌的分泌因子会导致肺上皮屏障破坏：利用气液界面细胞培养模型进行的研究

研究了烟曲霉条件培养基（AFCM）对Calu-3细胞肺上皮屏障完整性的影响。AFCM导致上皮间电阻的降低和上皮屏障中的闭塞蛋白网络的破坏。用蛋白酶抑制剂预孵育可使AFCM的效果降低约90%，证明真菌蛋白酶在上皮屏障破坏中的作用。通过质谱分析，我们在AFCM中鉴定出494个独特的蛋白，包括14个不同家族的肽酶。总之，这些发现表明烟曲霉分泌的蛋白酶能够在真菌感染过程中调节宿主上皮屏障的破坏。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical mycology 医学-兽医学

CiteScore

5.70

自引率

3.40%

发文量

632

审稿时长

12 months

期刊介绍： Medical Mycology is a peer-reviewed international journal that focuses on original and innovative basic and applied studies, as well as learned reviews on all aspects of medical, veterinary and environmental mycology as related to disease. The objective is to present the highest quality scientific reports from throughout the world on divergent topics. These topics include the phylogeny of fungal pathogens, epidemiology and public health mycology themes, new approaches in the diagnosis and treatment of mycoses including clinical trials and guidelines, pharmacology and antifungal susceptibilities, changes in taxonomy, description of new or unusual fungi associated with human or animal disease, immunology of fungal infections, vaccinology for prevention of fungal infections, pathogenesis and virulence, and the molecular biology of pathogenic fungi in vitro and in vivo, including genomics, transcriptomics, metabolomics, and proteomics. Case reports are no longer accepted. In addition, studies of natural products showing inhibitory activity against pathogenic fungi are not accepted without chemical characterization and identification of the compounds responsible for the inhibitory activity.